Jorn Drappa Sells 2,447 Shares of Alumis (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS) insider Jorn Drappa sold 2,447 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the transaction, the insider owned 56,892 shares in the company, valued at approximately $1,500,242.04. This trade represents a 4.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Alumis Trading Up 2.5%

Alumis stock opened at $27.80 on Friday. The firm has a market capitalization of $3.54 billion, a P/E ratio of -14.04 and a beta of -0.69. The business has a 50-day moving average of $25.50 and a 200-day moving average of $25.25. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. Research analysts anticipate that Alumis Inc. will post -2.87 EPS for the current fiscal year.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Institutional ownership has generally increased, including a significant expansion of Geode Capital Management’s position and additional buying by Goldman Sachs, Rhumbline Advisers and other investors. Such activity may provide some support for Alumis shares, although the reported purchases occurred in prior quarters.
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating on ALMS and maintained a $25 price target, suggesting the firm does not currently see a catalyst strong enough to support a more bullish outlook. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six insiders collectively sold 14,953 shares of Alumis at an average price of $26.37, generating approximately $394,311. Sellers included CFO John R. Schroer, whose position fell 11.72%, along with Mark Christopher Bradley, Jorn Drappa, David M. Goldstein, Roy C. Hardiman and Sanam Pangali. The transactions reduced individual holdings by roughly 1.28% to 12.28% and could weigh on investor sentiment because of the concentration of sales. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook. Alumis Insider Sale Filings
• Negative Sentiment: Alumis remains a clinical-stage biotechnology company with substantial losses. Its latest quarterly results missed both earnings and revenue expectations, while analysts forecast a full-year loss of approximately $2.87 per share. This limits fundamental support until the company reports meaningful clinical or development progress.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ALMS. Swiss National Bank bought a new stake in Alumis in the 1st quarter valued at approximately $2,815,000. Elmind Capital LP acquired a new position in Alumis during the 1st quarter worth approximately $2,864,000. Stempoint Capital LP bought a new position in shares of Alumis during the 1st quarter worth approximately $5,057,000. Janus Henderson Group PLC bought a new position in shares of Alumis during the 1st quarter worth approximately $46,790,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Alumis in the first quarter valued at approximately $8,648,000.

Analyst Upgrades and Downgrades

ALMS has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research note on Friday, May 15th. HC Wainwright reiterated a “neutral” rating and set a $25.00 target price on shares of Alumis in a report on Monday. Finally, Citigroup reissued a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.